The standard schedule (most patients)
| Phase | Duration | Dose | Purpose |
|---|---|---|---|
| Starter | Week 1-4 | 0.25mg weekly | Tolerability dose. Sub-therapeutic for weight loss. |
| First escalation | Week 5-8 | 0.5mg weekly | Therapeutic dose. Weight loss begins for most patients. |
| Second escalation (optional) | Week 9+ | 1.0mg weekly | Maximum Ozempic dose. Used if 0.5mg response is inadequate after 2-3 months. |
Slow titration (sensitive patients)
Slow titration spaces dose increases 6-8 weeks apart instead of the standard 4 weeks. Indications:
- Prior intolerance to other medications (particularly GI side effects)
- High anxiety about side effects (patient-driven decision)
- History of pancreatitis or gallbladder issues
- Advanced age (over 70)
- Significant baseline GI symptoms (IBS, gastroparesis)
- Patients who tried fast titration and discontinued due to side effects
| Phase | Duration | Dose |
|---|---|---|
| Starter | Week 1-8 | 0.25mg weekly |
| First escalation | Week 9-16 | 0.5mg weekly |
| Second escalation | Week 17+ | 1.0mg weekly (if needed) |
Slow titration adds ~2 months to reach maintenance but dramatically improves comfort. The overall weight loss trajectory at 12 months is similar to standard titration.
When to NOT escalate
Stay at your current dose if any of the following apply:
- Significant ongoing side effects. Persistent nausea, vomiting, or GI symptoms at current dose.
- Adequate weight loss progress. If you’re losing weight steadily at 0.5mg, there is no benefit to escalating.
- Recent illness or stress. Postpone escalation if your body is dealing with infection, travel disruption, or other stressors.
- Pregnancy planning approaching. Don’t escalate if you’ll be discontinuing soon for conception.
- Pharmacy supply pressure. If the higher dose is out of stock, don’t dial higher than what’s available on your current pen.
When to step DOWN a dose
Sometimes the right move is to reduce dose rather than escalate or discontinue:
- Intolerable side effects at new dose. Go back to previous dose for 2-4 weeks, then attempt escalation again with closer monitoring.
- Excessive weight loss. Some patients lose weight faster than is clinically ideal, stepping down to 0.5mg slows the trajectory.
- Approaching goal weight. Many patients drop from 1.0mg to 0.5mg once near goal weight to slow the loss and stabilise at a comfortable dose.
- Approaching pregnancy attempt. Gradual reduction before discontinuation is sometimes preferred.
The 0.5mg vs 1.0mg decision
A common misconception is that 1.0mg is always better than 0.5mg. In practice:
- 0.5mg is sufficient for many patients. Significant weight loss is achievable at 0.5mg; many patients reach their goals without ever needing 1.0mg.
- 1.0mg costs the same as 0.5mg. Manufacturer pricing is dose-flat; cost is not a factor.
- Higher dose can mean more side effects. Particularly during the escalation period; tolerability often drops at 1.0mg.
- 1.0mg is appropriate when 0.5mg has plateaued. If you’ve been on 0.5mg for 2-3 months with no continued weight loss, escalating is reasonable.
- For deeper response, consider Wegovy or Mounjaro. If 1.0mg Ozempic is insufficient, the next escalation is switching to a different drug rather than higher Ozempic dose. Ozempic vs Wegovy comparison.
Side effect management at each dose level
| Dose | Typical side effects | Management focus |
|---|---|---|
| 0.25mg | Mild nausea (week 1-2), reduced appetite begins | Smaller meals, hydration, avoid heavy/fatty foods |
| 0.5mg | Brief return of nausea (week 1-2 after escalation), then adaptation | Same as above + adjust meal timing to avoid evening nausea |
| 1.0mg | Strongest GI effects; constipation more common; fatigue possible | Fibre + hydration for constipation; assess if response justifies side effects |